This initiative will provide two years of support for planning activities necessary for initiating a Phase III clinical trial designed to validate VCID biomarkers and/or treat patients with VCID.
The full spectrum of VCID is in scope, and the one or more VCID disorders(s) to be targeted in the
credit:
trial must be clearly specified in the application, for example (but not limited to):
vascular insults including clinical stroke, silent infarcts and microinfarcts, leukoaraiosis, cerebral amyloid angiopathy (CAA), transient ischemic attack (TIA), micro-bleeds, CADASIL, and vascular contributions to Alzheimers dementia.
Planning activities may include identifying trial sites/collaborations, designing trial protocols and procedures, and addressing regulatory approvals.